

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 September 2022 (15.09.2022)



(10) International Publication Number
WO 2022/189656 A1

(51) International Patent Classification:
C12N 15/86 (2006.01) C07K 14/74 (2006.01)

(21) International Application Number:
PCT/EP2022/056390

(22) International Filing Date:
11 March 2022 (11.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21305317.6 12 March 2021 (12.03.2021) EP

(71) Applicants: INSTITUT PASTEUR [FR/FR]; 25-28, rue du Docteur Roux, 75724 PARIS CEDEX 15 (FR). THER-AVECTYS [FR/FR]; Bâtiment Pasteur Biotop 28 rue du Docteur Roux, 75724 PARIS CEDEX 15 (FR).

(72) Inventors: CHARNEAU, Pierre; Pasteur-TheraVectys Joint Lab Institut Pasteur, 28 rue du Dr Roux, 75724 PARIS CEDEX 15 (FR). MAJLESSI, Laleh; Pasteur-TheraVectys Joint Lab Institut Pasteur, 28 rue du Dr Roux, 75724 PARIS CEDEX 15 (FR). LOPEZ, Jodie; Pasteur-TheraVectys Joint Lab Institut Pasteur, 28 rue du Dr Roux, 75724 PARIS CEDEX 15 (FR). ANNA, François; Pasteur-TheraVectys Joint Lab Institut Pasteur, 28 rue du Dr Roux, 75724 PARIS CEDEX 15 (FR). BLANC, Catherine; Pasteur-TheraVectys Joint Lab Institut Pasteur, 28 rue du Dr Roux, 75724 PARIS CEDEX 15 (FR). MONCOQ, Fanny; Pasteur-TheraVectys Joint Lab Institut Pasteur, 28 rue du Dr Roux, 75724 PARIS CEDEX 15 (FR).

(74) Agent: ERNEST GUTMANN - YVES PLASSERAUD SAS; 66, rue de la Chaussée d'Antin, 75009 PARIS (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: LENTIVIRAL VECTORS TARGETING ANTIGENS TO MHC-II PATHWAY AND INDUCING PROTECTIVE CD8+ AND CD4+ T-CELL IMMUNITY IN A HOST

(57) Abstract: A recombinant lentiviral vector genome comprising a polynucleotide encoding a fusion polypeptide, wherein said fusion polypeptide comprises, arranged from N-terminal to C-terminal ends: a first polypeptide comprising (i) an MHC-II-associated light invariant chain (li), or (ii) the transmembrane domain of the transferrin receptor (TfR) and at least one antigenic polypeptide of a pathogen. The invention also relates to a lentiviral vector and pharmaceutical compositions comprising it.



WO 2022/189656 A1